Brokers Offer Predictions for MRVI Q1 Earnings

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) – Equities research analysts at KeyCorp issued their Q1 2027 earnings per share (EPS) estimates for Maravai LifeSciences in a research note issued on Wednesday, November 11th. KeyCorp analyst P. Knight anticipates that the company will post earnings of $0.00 per share for the quarter. KeyCorp currently has an “Overweight” rating and a $11.00 target price on the stock. The consensus estimate for Maravai LifeSciences’ current full-year earnings is ($0.16) per share. KeyCorp also issued estimates for Maravai LifeSciences’ Q2 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.05) EPS and FY2028 earnings at ($0.13) EPS.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03. The business had revenue of $45.85 million during the quarter, compared to the consensus estimate of $43.56 million. Maravai LifeSciences had a negative return on equity of 12.44% and a negative net margin of 30.83%.

Other equities research analysts have also recently issued research reports about the company. TD Cowen assumed coverage on Maravai LifeSciences in a research note on Monday, October 5th. They issued a “buy” rating and a $9.00 price objective for the company. Wall Street Zen upgraded shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Wells Fargo & Company raised their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research report on Friday, August 7th. UBS Group lifted their target price on shares of Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.10.

View Our Latest Stock Analysis on MRVI

Maravai LifeSciences Trading Down 1.9%

NASDAQ:MRVI opened at $7.40 on Tuesday. The company has a market capitalization of $1.92 billion, a PE ratio of -17.21 and a beta of 0.61. Maravai LifeSciences has a 52-week low of $2.80 and a 52-week high of $9.42. The stock’s 50 day moving average price is $7.40 and its 200 day moving average price is $5.44. The company has a quick ratio of 2.98, a current ratio of 4.66 and a debt-to-equity ratio of 0.51.

Hedge Funds Weigh In On Maravai LifeSciences

Several institutional investors have recently added to or reduced their stakes in MRVI. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Maravai LifeSciences in the third quarter valued at about $5,259,000. Marshall Wace LLP boosted its stake in shares of Maravai LifeSciences by 38.2% during the 3rd quarter. Marshall Wace LLP now owns 2,034,070 shares of the company’s stock worth $15,581,000 after acquiring an additional 562,593 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Maravai LifeSciences by 64.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company’s stock worth $4,015,000 after acquiring an additional 558,050 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Maravai LifeSciences by 24.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 2,043,668 shares of the company’s stock worth $15,654,000 after acquiring an additional 402,371 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Maravai LifeSciences in the 2nd quarter worth approximately $2,230,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

About Maravai LifeSciences

(Get Free Report)

Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.

Recommended Stories

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.